TNSN08064A1 - Albumin fusion proteins - Google Patents

Albumin fusion proteins

Info

Publication number
TNSN08064A1
TNSN08064A1 TNP2008000064A TNSN08064A TNSN08064A1 TN SN08064 A1 TNSN08064 A1 TN SN08064A1 TN P2008000064 A TNP2008000064 A TN P2008000064A TN SN08064 A TNSN08064 A TN SN08064A TN SN08064 A1 TNSN08064 A1 TN SN08064A1
Authority
TN
Tunisia
Prior art keywords
fusion proteins
albumin fusion
nucleic acids
vectors
host cells
Prior art date
Application number
TNP2008000064A
Inventor
Adam Bell
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Craig Rosen
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of TNSN08064A1 publication Critical patent/TNSN08064A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
TNP2008000064A 2005-08-12 2008-02-11 Albumin fusion proteins TNSN08064A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
TNSN08064A1 true TNSN08064A1 (en) 2009-07-14

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000064A TNSN08064A1 (en) 2005-08-12 2008-02-11 Albumin fusion proteins

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101184391B1 (en) 2004-02-09 2013-03-14 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US8334365B2 (en) 2006-06-07 2012-12-18 Human Genome Sciences, Inc. Albumin fusion proteins
AU2007294805A1 (en) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA3001783C (en) 2007-01-30 2020-09-08 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
AU2009256547B2 (en) 2008-06-13 2014-07-10 Proyecto De Biomedicina Cima, S.L. Apo-A conjugates for the administration of biologically active compounds
US20100227818A1 (en) 2009-01-16 2010-09-09 Teva Biopharmaceuticals Usa, Inc. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor For The Prevention Of Neutropenia
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
CA2772051C (en) 2009-08-24 2020-08-18 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
KR20130070576A (en) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 Albumin derivatives and variants
EP2571992B1 (en) * 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
JP5948683B2 (en) * 2011-02-28 2016-07-06 国立研究開発法人国立循環器病研究センター Medicament for inhibiting malignant tumor metastasis
CN110272484A (en) 2011-05-05 2019-09-24 阿尔布梅迪克斯医疗有限公司 Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104383541A (en) 2011-10-21 2015-03-04 艾伯维公司 Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
PT107924A (en) 2011-10-21 2014-12-03 Abbvie Inc TREATMENT OF AAD COMBINATION (EG WITH ABT-072 OR ABT-333) FOR USE IN HCV TREATMENT
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
SI2804623T1 (en) 2012-01-12 2020-02-28 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EA201491470A1 (en) 2012-02-15 2015-01-30 Амуникс Оперэйтинг Инк. COMPOSITIONS OF FACTOR VIII AND METHODS OF OBTAINING AND USING SIMILAR
PL2825556T3 (en) 2012-03-16 2018-10-31 Albumedix A/S Albumin variants
JP2015525222A (en) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Chimeric coagulation factor
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
RS59876B1 (en) 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
CN105452290A (en) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 Albumin variants
RS61387B2 (en) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Optimized factor viii gene
KR20150118123A (en) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 Pharmacokinetic animal model
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
KR20240023705A (en) 2013-06-28 2024-02-22 바이오버라티브 테라퓨틱스 인크. Thrombin cleavable linker with xten and its uses thereof
TWI667255B (en) 2013-08-14 2019-08-01 美商生物化學醫療公司 Factor viii-xten fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
HRP20240640T1 (en) 2014-01-10 2024-08-02 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
DK3207130T3 (en) 2014-10-14 2019-11-11 Halozyme Inc Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof, and Methods for Using the Same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
US10633428B2 (en) 2015-08-20 2020-04-28 Albumedix Ltd Albumin variants and conjugates
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
ES2926585T3 (en) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Optimized Factor VIII genes
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
MA46967A (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS
MA47163A (en) 2016-12-16 2019-11-06 Biogen Ma Inc PROTEOLYTICALLY STABILIZED ACTIVATED GROWTH DIFFERENTIATION FACTOR 11
MX2019009063A (en) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
WO2018193033A1 (en) * 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
US20210163986A1 (en) 2017-08-09 2021-06-03 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
MA52630A (en) 2018-05-18 2021-05-26 Bioverativ Therapeutics Inc HEMOPHILIA A TREATMENT METHODS
CN113227385A (en) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use for non-viral gene therapy
MX2021006648A (en) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix.
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JPWO2022030580A1 (en) * 2020-08-06 2022-02-10
WO2024080306A1 (en) * 2022-10-11 2024-04-18 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and physiologically-active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060071A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
KR101184391B1 (en) * 2004-02-09 2013-03-14 휴먼 게놈 사이언시즈, 인코포레이티드 Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
EP1924596A4 (en) 2009-07-29
MA29836B1 (en) 2008-10-03
KR20080071119A (en) 2008-08-01
ECSP088262A (en) 2008-05-30
EP1924596A2 (en) 2008-05-28
BRPI0614761A2 (en) 2009-05-19
IL189246A0 (en) 2008-08-07
CA2618476A1 (en) 2007-02-22
WO2007021494A2 (en) 2007-02-22
WO2007021494A3 (en) 2007-07-26
AU2006280312A1 (en) 2007-02-22
NO20081233L (en) 2008-05-09
JP2009504157A (en) 2009-02-05
MX2008001865A (en) 2008-04-15

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
WO2007146038A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2001079444A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
HK1205193A1 (en) Recombinant n-glycosylated proteins from procaryotic cells n-
EA201690946A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EA201171220A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EA201990619A1 (en) FGF21 MUTANTS AND THEIR APPLICATION
WO2005063820A3 (en) Il-7 fusion proteins
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
IN2012DN02981A (en)
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
WO2006017355A3 (en) Improved aprotinin variants
WO2002097110A3 (en) TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins